Back to Journals » Patient Preference and Adherence » Volume 2

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease

Authors Amir Hayat, Dhiren Haria, Moro O Salifu

Published 6 August 2008 Volume 2008:2 Pages 195—200

DOI https://doi.org/10.2147/PPA.S2356

Amir Hayat, Dhiren Haria, Moro O Salifu

Division of Nephrology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA

Abstract: Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin is a hormone synthesized in the kidney responsible for red blood cell maturation in the bone marrow. It is deficient in the majority of patients with advanced kidney disease thereby predisposing to anemia. Since the approval of recombinant human erythropoietin (epoetin alfa) by the US FDA in 1989, epoetin alfa and similar agents now collectively known as erythropoietin stimulating agents (ESA) have become the standard of care for the treatment of the erythropoietin-deficient anemia that occurs in most patients with CKD. In this review, we have outlined the considerations that need to be taken into account when prescribing ESA for the treatment of anemia in CKD.

Keywords: erythropoietin stimulating agents, chronic kidney disease, anemia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation – safety, efficacy, and patient adherence

Lloret MJ, Ruiz-García C, DaSilva I, Furlano M, Barreiro Y, Ballarín J, Bover J

Patient Preference and Adherence 2013, 7:1147-1156

Published Date: 6 November 2013

Pars plana vitrectomy for malignant glaucoma in nonglaucomatous and in filtered glaucomatous eyes

Matlach J, Slobodda J, Grehn F, Klink T

Clinical Ophthalmology 2012, 6:1959-1966

Published Date: 27 November 2012

Trabeculectomy with double low dose of mitomycin C – two years of follow-up

Errico D, Scrimieri F, Riccardi R, Fedeli R, Iarossi G

Clinical Ophthalmology 2011, 5:1679-1686

Published Date: 1 December 2011

Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin

Anbu Pandian, Anjali Arora, Laurence S Sperling, Bobby V Khan

Vascular Health and Risk Management 2008, 4:1001-1009

Published Date: 10 October 2008

Quality of life assessment in clinical research on Chinese medicine: Early experience and outlook

Lai Yi Eliza Wong, Ping Chung Leung

Patient Preference and Adherence 2008, 2:241-246

Published Date: 15 September 2008

Patient’s compliance with allergen immunotherapy

Cristoforo Incorvaia, Marina Mauro, Erminia Ridolo, Paola Puccinelli, Massimiliano Liuzzo, et al

Patient Preference and Adherence 2008, 2:247-251

Published Date: 15 September 2008

Patient attitudes toward the use of surgical scrubs in a military hospital clinic

Jon D Lund, James E Rohrer, Susana Goldfarb

Patient Preference and Adherence 2008, 2:185-188

Published Date: 26 June 2008

Interactions among physicians, patients, and first-degree relatives in the familial screening of colorectal cancer in France

Isabelle Ingrand, Sarah Dujoncquoy, Virginie Migeot, Véronique Ghadi, Michel Beauchant, Pierre Ingrand

Patient Preference and Adherence 2008, 2:47-55

Published Date: 13 March 2008